ChiCTR2100044406 版本V1.0 版本创建时间2021/09/21 01:32:05 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100044406 

最近更新日期:

Date of Last Refreshed on:

2021-03-18 03:22:34 

注册时间:

Date of Registration:

2021-03-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

全身振动治疗对脊髓损伤慢性期患者直立耐受性的生理效应研究

Public title:

research of physiological effects of whole body vibration (WBV) on orthostatic tolerance in individuals with chronic spinal cord injury

注册题目简写:

English Acronym:

研究课题的正式科学名称:

全身振动治疗对脊髓损伤慢性期患者直立耐受性的生理效应研究

Scientific title:

research of physiological effects of whole body vibration (WBV) on orthostatic tolerance in individuals with chronic spinal cord injur

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李琳 

研究负责人:

李琳 

Applicant:

Lin Li 

Study leader:

Lin Li 

申请注册联系人电话:

Applicant telephone:

15257197131

研究负责人电话:

Study leader's
telephone:

15257197131

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

danella@126.com

研究负责人电子邮件:

Study leader's E-mail:

danella@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市灵隐路12号

研究负责人通讯地址:

浙江省杭州市灵隐路12号

Applicant address:

No. 12 Lingyin Road, Hangzhou City, Zhejiang Province

Study leader's address:

No. 12 Lingyin Road, Hangzhou City, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江医院

Applicant's institution:

Zhejiang Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020临审第(20K)号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

浙江医院伦理审查委员会

Name of the ethic committee:

Ethics Committee of Zhejiang Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

李卫

Contact Name of the ethic committee:

Wei Li

伦理委员会联系地址:

浙江省杭州市灵隐路12号

Contact Address of the ethic committee:

No. 12 Lingyin Road, Hangzhou City, Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江医院

Primary sponsor:

Zhejiang Hospital

研究实施负责(组长)单位地址:

浙江医院

Primary sponsor's address:

Zhejiang Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江医院

具体地址:

灵隐路12号

Institution
hospital:

Zhejiang Hospital

Address:

12 Lingyin Road

经费或物资来源:

浙江省科技厅

Source(s) of funding:

Zhejiang provincial department of Science and Technology

研究疾病:

脊髓损伤  

Target disease:

spinal cord injury

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

本项目拟采用病例对照研究方法,观察不同频率全身振动治疗对 ASIA A 级、B 级脊髓损伤慢性期患者不同体位的血流动力学指标、症状评估量表的即刻影响,具体如下:(1)明确全身振动治疗对 ASIA A 级、B 级脊髓损伤慢性期患者不同体位下血流动力学指标、主观症状评估的即时效应。(2) 阐明不同的全身振动频率参数对 ASIA A 级、B 级脊髓损伤慢性期患者血流动力学指标、主观症状评估的不同效应,明确治疗脊髓损伤患者直立位不耐受最科学、安全、舒适的全身振动参数设置。  

Objectives of Study:

(1) To clarify the immediate effects of WBV on the evaluation of hemodynamic indicators and subjective symptoms in patients with spinal cord injuries( grade A or B on ASIA impairment scale). (2) To clarify the different effects of different vibration frequencies on the hemodynamic indicators and subjective symptom assessment of patients with spinal cord injury. And to identify the most scientific prescriptiont of WBV treatment in dealing with orthostatic tolerance in patients with spinal cord injury.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

损伤平面在C4-T6 ,年龄30-70岁,生命体征稳定,无心脑血管疾病,未服用影响血压的药物。

Inclusion criteria

With motor complete injury levels T6 and above,grade A or B on ASIA impairment scale≥3 months post-injury,aged 30-70 years old, with stable vital signs, no cardiovascular and cerebrovascular diseases, and no drugs that affect blood pressure intake.

排除标准:

有高血压病、心功能不全等影响心血管功能的基础疾病者,在服用影响血压水平的药物者。严重肝肾功能不全等其他系统疾病者。

Exclusion criteria:

Those who had basic diseases that affect cardiovascular function, such as hypertension and cardiac insufficiencyare. And those who took drugs that affect blood pressure levels. Severe liver or kidney dysfunction and other system diseases.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-04-01 00:00:00 To 2022-06-30 00:00:00

干预措施:

Interventions:

组别:

振动治疗组

样本量:

20

Group:

WBV treatment group

Sample size:

干预措施:

全身振动治疗20Hz

干预措施代码:

Intervention:

whole body vibration 20Hz

Intervention code:

组别:

振动治疗组

样本量:

20

Group:

WBV treatment group

Sample size:

干预措施:

全身振动治疗 30Hz

干预措施代码:

Intervention:

whole body vibration 30Hz

Intervention code:

组别:

振动治疗组

样本量:

20

Group:

WBV treatment group

Sample size:

干预措施:

全身振动治疗 10Hz

干预措施代码:

Intervention:

whole body vibration 10Hz

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江医院 

单位级别:

三级甲等 

Institution
hospital:

zhejiang Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

每搏输出量指数

指标类型:

主要指标

Outcome:

stroke volume index, SVI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心输出量指数

指标类型:

主要指标

Outcome:

cardiac output index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均动脉压

指标类型:

主要指标

Outcome:

mean arterial pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

主要指标

Outcome:

heart rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总外周阻力指数

指标类型:

主要指标

Outcome:

total peripheral resistance index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体位性低血压症状评估量表

指标类型:

主要指标

Outcome:

orthostatic hypotension symptom assessment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

去甲肾上腺素

指标类型:

主要指标

Outcome:

noradrenaline

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血管紧张素 II

指标类型:

主要指标

Outcome:

angiotension II

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

醛固酮

指标类型:

主要指标

Outcome:

aldosterone

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾素

指标类型:

主要指标

Outcome:

renin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

压力反射敏感性

指标类型:

主要指标

Outcome:

baroreflex sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机方案委托第三方机构进行实施。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random scheme is entrusted to a third party.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂不提供原始数据公众共享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No public sharing of original data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本课题的原始数据为CRF,原始数据必须有可溯源性。研究者手工填写CRF,定期收集,并采用双人双录入方法进行数据录入。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original data of this project is CRF, and the original data must be traceable. Researchers fill in CRF manually, collect it regularly, and use double entry method for data entry.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-03-18 03:22:34